Drug
Revusiran
Revusiran: highest development phase Phase 3, developed by Alnylam Pharmaceuticals. 2 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Alnylam Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| Revusiran (ALN-TTRSC) NCT02319005 | Phase 3 | Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC) |
| Revusiran NCT02595983 | Phase 2 | Transthyretin (TTR)-Mediated Amyloidosis |
Latest
No recent events.
Follow Revusiran on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.